Efficacy of MK0557 in Combination With Sibutramine or Orlistat

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00533481
First received: September 19, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted
  Purpose

Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.


Condition Intervention Phase
Obesity
Drug: MK0557
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: December 2003
Study Completion Date: December 2003
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women between the ages of 18-65 who are considered obese (have a body mass index between 30 and 43)

Exclusion Criteria:

  • Subject has high blood pressure or is taking any high blood pressure medicine
  • History of psychiatric disorder, stroke, or heart disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00533481

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00533481     History of Changes
Other Study ID Numbers: 2007_615
Study First Received: September 19, 2007
Last Updated: September 19, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on April 17, 2014